A Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease

SK chemicals

Status and phase: Completed; Phase 2

Conditions: Alzheimer's Disease

Treatments: Drug: SK-PC-B70M

Study type: Interventional

Funder types: Industry

Identifiers

NCT00443417

SMART_II_2006

Details and patient eligibility

About

The purpose of this study is to find optimistic dose and to evaluate the efficacy and safety of SK-PC-B70M in patients with mild to moderate Alzheimer's disease.

Enrollment: 188 estimated patients

Sex: All

Ages: 55 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age range : 50 ~ 85 years
• Clinical diagnosis of probable Alzheimer's disease (DSM-IV and NINCDS-ADRDA criteria)
• MRI within the last 12 months consistent with a diagnosis of AD
• MMSE score 10 to 26
• AChEI or memantine was discontinued at least 3 months prior to screening

Exclusion criteria

• Patient in mild cognitive impairment (MCI; CDR-SB <2.5)
• Other central nervous disease
• hypothyroidism, Vitamin B12/ Folic acid deficiency, hypercalcemia, neurosyphilis, AIDS
• T.I.A or Major infarction within the last 12 months
• Any serious disorder that could limit the ability of the patient to participate in the study
• COPD or asthma
• Any condition which would make the patient or the caregiver, in the opinion of the investigator, unsuitable for the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

188 participants in 4 patient groups, including a placebo group

1

Placebo Comparator group

Treatment:

Drug: SK-PC-B70M

2

Active Comparator group

Description:

200mg qd

Treatment:

Drug: SK-PC-B70M

3

Active Comparator group

Description:

200mg bid

Treatment:

Drug: SK-PC-B70M

4

Active Comparator group

Description:

400mg qd

Treatment:

Drug: SK-PC-B70M